Episode

Lululemon Faces Scrutiny, Peptides Go Clinical, Connection Economy Rises

Podcast
Fitt Insider
Published
Apr 15, 2026
Duration seconds
178
Processing state
not_requested
Canonical source
https://fittinsider.libsyn.com/lululemon-faces-scrutiny-peptides-go-clinical-connection-economy-rises
Audio
https://traffic.libsyn.com/secure/fittinsider/58_-_FI_Daily_Brief.mp3?dest-id=1477619
JSON
/v1/public/podcasts/fitt-insider-254580/episodes/lululemon-faces-scrutiny-peptides-go-clinical-connection-economy-rises
Markdown
/podcast/fitt-insider-254580/lululemon-faces-scrutiny-peptides-go-clinical-connection-economy-rises.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/fitt-insider-254580/episodes/lululemon-faces-scrutiny-peptides-go-clinical-connection-economy-rises/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/fitt-insider-254580/lululemon-faces-scrutiny-peptides-go-clinical-connection-economy-rises.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

April 15, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Protocole launches with $6M funding to build clinical-grade peptide platform connecting users to licensed clinicians and regulated pharmacies amid FDA scrutiny Posh raises $37M to scale real-world experiences as connection economy shifts from screens to in-person events, backed by Ari Emanuel and Mark Cuban Texas AG investigates Lululemon over potential health risks tied to "forever chemicals" as 70%+ of US adults worry about chemical exposure in clothing More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → [email protected]